HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial.

AbstractOBJECTIVE:
The aim was to compare the (sentinel) lymph node detection rate of indocyanine green (ICG)-fluorescent imaging versus standard-of-care 99m Tc-nanocoilloid for sentinel lymph node (SLN)-mapping.
BACKGROUND:
The current gold standard for axillary staging in patients with breast cancer is sentinel lymph node biopsy (SLNB) using radio-guided surgery using radioisotope technetium ( 99m Tc), sometimes combined with blue dye. A promising alternative is fluorescent imaging using ICG.
METHODS:
In this noninferiority trial, we enrolled 102 consecutive patients with invasive early-stage, clinically node-negative breast cancer. Patients were planned for breast conserving surgery and SLNB between August 2020 and June 2021. The day or morning before surgery, patients were injected with 99m Tc-nanocolloid. In each patient, SLNB was first performed using ICG-fluorescent imaging, after which excised lymph nodes were tested with the gamma-probe for 99m Tc-uptake ex vivo, and the axilla was checked for residual 99m Tc-activity. The detection rate was defined as the proportion of patients in whom at least 1 (S)LN was detected with either tracer.
RESULTS:
In total, 103 SLNBs were analyzed. The detection rate of ICG-fluorescence was 96.1% [95% confidence interval (95% CI)=90.4%-98.9%] versus 86.4% (95% CI=78.3%-92.4%) for 99m Tc-nanocoilloid. The detection rate for pathological lymph nodes was 86.7% (95% CI=59.5%-98.3%) for both ICG and 99m Tc-nanocoilloid. A median of 2 lymph nodes were removed. ICG-fluorescent imaging did not increase detection time. No adverse events were observed.
CONCLUSIONS:
ICG-fluorescence showed a higher (S)LN detection rate than 99m Tc-nanocoilloid, and equal detection rate for pathological (S)LNs. ICG-fluorescence may be used as a safe and effective alternative to 99m Tc-nanocoilloid for SLNB in patients with early-stage breast cancer.
AuthorsClaudia A Bargon, Anne Huibers, Danny A Young-Afat, Britt A M Jansen, Inne H M Borel-Rinkes, Jules Lavalaye, Henk-Jan van Slooten, Helena M Verkooijen, Christiaan F P van Swol, Annemiek Doeksen
JournalAnnals of surgery (Ann Surg) Vol. 276 Issue 5 Pg. 913-920 (11 01 2022) ISSN: 1528-1140 [Electronic] United States
PMID35894448 (Publication Type: Equivalence Trial, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • Coloring Agents
  • Radiopharmaceuticals
  • Technetium Tc 99m Aggregated Albumin
  • Technetium
  • Indocyanine Green
Topics
  • Breast Neoplasms (diagnostic imaging, pathology, surgery)
  • Coloring Agents
  • Female
  • Humans
  • Indocyanine Green
  • Lymph Nodes (diagnostic imaging, pathology)
  • Lymphoscintigraphy (methods)
  • Radiopharmaceuticals
  • Sentinel Lymph Node (diagnostic imaging, pathology, surgery)
  • Sentinel Lymph Node Biopsy (methods)
  • Technetium
  • Technetium Tc 99m Aggregated Albumin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: